EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy

Shiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, Shunsuke Oyamada, Tomoyuki Iwasaki, Ryunosuke Numakura, Yuya Yoshida, Sakura Taniguchi, Yuki Kasahara, Keigo Komine, Ken Saijo, Hidekazu Shirota und 1 weitere

European Journal of Cancer · 2026-06 · 242 · 116826

DOI: 10.1016/j.ejca.2026.116826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Shiori Ishikawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku Univers…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Biliary Tract Neoplasms, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Biliary Tract NeoplasmsMutationTumor Suppressor Protein p53Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsBiomarkers, TumorHumansFemaleCisplatinMaleDeoxycytidineMiddle AgedAgedGemcitabinePrognosis

Stichwörter der Autor:innen

Biliary tract cancerImmune checkpoint inhibitorKRASTP53

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanTumor Suppressor Protein p53CisplatinTP53 protein, humanDeoxycytidineGemcitabineImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Clinical Research Data Center, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan. Electronic address: kawakami_h@to…

Zitieren

APA

Ishikawa, S., Ouchi, K., Wakayama, S., Oyamada, S., Iwasaki, T., Numakura, R., Yoshida, Y., Taniguchi, S., Kasahara, Y., Komine, K., Saijo, K., Shirota, H., & Kawakami, H. (2026). Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European Journal of Cancer, 242, 116826. https://doi.org/10.1016/j.ejca.2026.116826

Vancouver

Ishikawa S, Ouchi K, Wakayama S, Oyamada S, Iwasaki T, Numakura R, et al. Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European Journal of Cancer. 2026;242:116826. doi:10.1016/j.ejca.2026.116826

BibTeX
@article{Ishikawa2026,
  author = {Ishikawa, Shiori and Ouchi, Kota and Wakayama, Shonosuke and Oyamada, Shunsuke and Iwasaki, Tomoyuki and Numakura, Ryunosuke and Yoshida, Yuya and Taniguchi, Sakura and Kasahara, Yuki and Komine, Keigo and Saijo, Ken and Shirota, Hidekazu and Kawakami, Hisato},
  title = {Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {242},
  pages = {116826},
  doi = {10.1016/j.ejca.2026.116826}
}
Kostenlos starten →